Neurocrine Biosciences, Inc. (NBIX) Insider Kyle Gano Sells 3,809 Shares

Share on StockTwits

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Kyle Gano sold 3,809 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.12, for a total value of $335,649.08. Following the completion of the sale, the insider now owns 17,595 shares in the company, valued at approximately $1,550,471.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NBIX traded down $0.65 on Thursday, hitting $83.75. 13,081 shares of the company were exchanged, compared to its average volume of 868,714. Neurocrine Biosciences, Inc. has a twelve month low of $64.72 and a twelve month high of $126.98. The stock has a market capitalization of $7.96 billion, a price-to-earnings ratio of 376.73, a PEG ratio of 2.06 and a beta of 1.89.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, February 5th. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.05. Neurocrine Biosciences had a return on equity of 5.32% and a net margin of 4.68%. The firm had revenue of $131.49 million during the quarter, compared to analysts’ expectations of $132.32 million. During the same period in the previous year, the firm posted $0.07 EPS. Neurocrine Biosciences’s revenue for the quarter was up 39.1% on a year-over-year basis. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 1.77 EPS for the current year.

A number of research firms have commented on NBIX. Bank of America reduced their target price on Neurocrine Biosciences from $124.00 to $117.00 and set a “buy” rating on the stock in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Neurocrine Biosciences in a research report on Wednesday. Canaccord Genuity began coverage on Neurocrine Biosciences in a research report on Wednesday, November 21st. They issued a “buy” rating and a $111.00 target price on the stock. Oppenheimer set a $140.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Monday, November 5th. Finally, Needham & Company LLC set a $104.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, December 12th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $102.28.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Financial Architects Inc grew its stake in Neurocrine Biosciences by 283.7% during the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock worth $170,000 after purchasing an additional 1,024 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Neurocrine Biosciences during the 3rd quarter worth $234,000. Dupont Capital Management Corp grew its stake in Neurocrine Biosciences by 160.8% during the 3rd quarter. Dupont Capital Management Corp now owns 12,912 shares of the company’s stock worth $1,588,000 after purchasing an additional 7,961 shares in the last quarter. Opera Trading Capital purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth about $449,000. Finally, Barings LLC purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth about $3,097,000. 97.82% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4132860/neurocrine-biosciences-inc-nbix-insider-kyle-gano-sells-3809-shares.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Read More: How does a reverse stock split work?

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jonathan Corr Sells 12,515 Shares of Ellie Mae Inc  Stock
Jonathan Corr Sells 12,515 Shares of Ellie Mae Inc Stock
T-Mobile Us Inc  Insider Thomas Christopher Keys Sells 43,000 Shares
T-Mobile Us Inc Insider Thomas Christopher Keys Sells 43,000 Shares
Astrotech  Shares Up 6.5%
Astrotech Shares Up 6.5%
Teekay Offshore Partners  Trading 5.2% Higher
Teekay Offshore Partners Trading 5.2% Higher
Workiva  Issues Q1 2019 Earnings Guidance
Workiva Issues Q1 2019 Earnings Guidance
Autolus Therapeutics Ltd –  Receives $44.00 Consensus PT from Analysts
Autolus Therapeutics Ltd – Receives $44.00 Consensus PT from Analysts


Leave a Reply

© 2006-2019 Ticker Report